|Assessment Status||Rapid review complete|
|Indication||As monotherapy for the treatment of patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors|
|Rapid review commissioned||01/09/2021|
|Rapid review completed||28/09/2021|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that entrectinib not be considered for reimbursement at the submitted price*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations June 2022.